Stock 600572 ZHEJIANG CONBA PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Zhejiang CONBA Pharmaceutical Co.,Ltd.

Equities

600572

CNE000001H86

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-17 pm EDT 		5-day change 1st Jan Change
5.02 CNY -1.18% Intraday chart for Zhejiang CONBA Pharmaceutical Co.,Ltd. +2.24% -0.59%
Apr. 01 Tranche Update on Zhejiang CONBA Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on January 23, 2024. CI
Feb. 02 Shanghai-Listed Firms Actively Repurchase Shares as Regulators Focus on Market Value MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Tranche Update on Zhejiang CONBA Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on January 23, 2024.
CI
Shanghai-Listed Firms Actively Repurchase Shares as Regulators Focus on Market Value
MT
Shanghai Dingjia Trading Co., Ltd. agreed to acquire 20% stake in Shanghai Kede Network Technology Co., Ltd. from Zhejiang CONBA Pharmaceutical Co.,Ltd. for CNY 26 million.
CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. announces an Equity Buyback for CNY 400 million worth of its shares.
CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. authorizes a Buyback Plan.
CI
CONBA Pharma Gets Nod to Trial Cough Medicine
MT
CONBA Pharma Unit's Acetyl Cysteine Granules Chosen for China's Centralized Drug Procurement
MT
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Zhejiang CONBA Pharmaceutical Co.,Ltd.(XSSC:600572) added to S&P Global BMI Index
CI
Zhejiang CONBA Pharmaceutical Co.,Ltd.(XSSC:600572) added to FTSE All-World Index
CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Wuxi China Life Chengda Equity Investment Center (Limited Partnership) and Jinhua Future Yicai Phase I Equity Investment Partnership (Limited Partnership) completed the acquisition of 7.84% stake in Jiangxi Zhenshiming Pharmaceutical Co., Ltd. from Zhejiang CONBA Pharmaceutical Co.,Ltd.
CI
CONBA Pharma Gets Drug Registration for Risperidone Oral Solution
MT
Wuxi China Life Chengda Equity Investment Center (Limited Partnership) and Jinhua Future Yicai Phase I Equity Investment Partnership (Limited Partnership) intends to acquire 7.84% stake in Jiangxi Zhenshiming Pharmaceutical Co., Ltd. from Zhejiang CONBA Pharmaceutical Co.,Ltd for CNY 290 million.
CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Zhejiang CONBA Pharmaceutical to Sell 7.8% Stake in Pharma Firm
CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. acquired remaining 7.6665% stake in Zhejiang CONBA Health Technology Co., Ltd from Gao Jing and Hu Xiaodan for CNY 21.9 million.
CI
Zhejiang Int'l Group Co.,Ltd. announced that it has received CNY 399.999996 million in funding from Zhejiang CONBA Pharmaceutical Co.,Ltd.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600572 Stock
  4. News Zhejiang CONBA Pharmaceutical Co.,Ltd.